Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Citi
Healthtrust
Moodys
Colorcon
AstraZeneca
Mallinckrodt
Federal Trade Commission
Accenture

Generated: August 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Formoterol process
Abstract:A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.
Inventor(s): Gao; Yun (Southborough, MA), Hett; Robert (Aarau, CH), Fang; Kevin Q. (Wellesley, MA), Wald; Stephen A. (Sudbury, MA), Redmon; Martin P. (Marlborough, MA), Senanayake; Chris Hugh (Shrewsbury, MA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:09/083,010
Patent Claims: 1. Crystalline R,R-formoterol L-(+)-tartrate.

2. Solid R,R-formoterol L-(+)-tartrate having a melting point greater than 179.degree. C.

3. A polymorph of R,R-formoterol L-(+)-tartrate having a transition point in differential scanning calorimetry of about 193.degree. C. and a solubility in water at 25.degree. C. of about 15 mg/mL.

4. A polymorph of R,R-formoterol L-(+)-tartrate having a transition point in differential scanning calorimetry of about 180.degree. C. and a solubility in water at 25.degree. C. of greater than 25 mg/mL.

5. A pharmaceutical composition comprising R,R-formoterol L-(+)-tartrate and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition according to claim 5 wherein said pharmaceutically acceptable carrier is substantially lactose-free.

7. An aerosol pharmaceutical composition according to claim 5.

8. An oral pharmaceutical composition according to claim 5.

9. An oral pharmaceutical composition according to claim 8 in the form of a tablet, capsule or syrup.

10. A dry powder pharmaceutical composition for inhalation according to claim 5 comprising R,R-formoterol L-(+)-tartrate and a dry, solid carrier having a mean particle size between 1 .mu.m and 100 .mu.m.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Express Scripts
Baxter
Harvard Business School
Cerilliant
Boehringer Ingelheim
US Army
Mallinckrodt
Deloitte
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot